Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 2/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28751377 | 0.90 | LMNA (0.52) | LMNAMCL1POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL927698 | 0.88 | ESR1 (0.57) | LMNAMCL1POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL13986553 | 0.88 | MCL1 (0.62) | LMNAMCL1POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL5253603 | 0.87 | MMP8 (0.53) | LMNAMCL1POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL5569768 | 0.87 | LMNA (0.67) | LMNAMCL1POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL2518056 | 0.87 | LMNA (0.50) | LMNAMCL1POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL2518060 | 0.87 | LMNA (0.50) | LMNAMCL1POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL18041161 | 0.87 | LMNA (0.67) | LMNAMCL1POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL15280428 | 0.87 | LMNA (0.67) | LMNAMCL1POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL15280427 | 0.87 | LMNA (0.67) | LMNAMCL1POLBAPOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | LMNA 1943/4885MCL1 3297/4885POLB 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.